-
Mar.312020NEWS
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED
Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED
-
Feb.272020NEWS
HanAll Biopharma Recorded Its Record-High Earnings Last Year
HanAll Biopharma Recorded Its Record-High Earnings Last Year
-
Jan.282020NEWS
HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3(VELOS-2) Study at a Press Conference
HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3(VELOS-2) Study at a Press Conf..
-
Mar.122019NEWS
HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease
HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease
-
Oct.292018NEWS
HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S.
HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innova..
-
Oct.012018NEWS
HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China
HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND i..